GLUE May 2024 5.000 put
| Previous close | 0.4000 |
| Open | 0.2500 |
| Bid | 0.0000 |
| Ask | 0.4000 |
| Strike | 5.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.2500 - 0.4000 |
| Contract range | N/A |
| Volume | |
| Open interest | 205 |
GlobeNewswireMonte Rosa Therapeutics Announces Pricing of $100 Million Underwritten Public Offering
BOSTON, May 16, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the pricing of an underwritten public offering of 10,638,476 shares of its common stock at a public offering price of $4.70 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 10,638,524 shares of common stock at a public offering price o
- GlobeNewswire
Monte Rosa Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
BOSTON, May 15, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. All of the shares of common stock and pre-funded warrants to purchase shares of common stock in th
- GuruFocus.com
Monte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview
Insight into Financial Performance and Strategic Developments Amidst Ongoing Clinical Trials
